Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease

Trial Profile

Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Hodgkin's disease; Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Actual patient number is 39 according to ClinicalTrials.gov.
    • 05 Jun 2012 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top